BioCentury
ARTICLE | Clinical News

AST-OPC1: Phase I/IIa started

April 6, 2015 7:00 AM UTC

Asterias began an open-label, dose-escalation, U.S. Phase I/IIa trial to evaluate single injections of 2 million or 10 million cells of AST-OPC1 and 2 injections of 10 million cells of AST-OPC1 in abo...